Filing Details

Accession Number:
0001209191-20-055590
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-10-22 17:36:19
Reporting Period:
2020-10-20
Accepted Time:
2020-10-22 17:36:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1348911 Kalvista Pharmaceuticals Inc. KALV Pharmaceutical Preparations (2834) 200915291
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1691102 Christopher Yea C/O Kalvista Pharmaceuticals, Inc
55 Cambridge Parkway, Suite 901E
Cambridge MA 02142
Chief Development Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-10-20 5,640 $17.27 76,315 No 4 S Direct
Common Stock Disposition 2020-10-20 2,302 $18.01 74,013 No 4 S Direct
Common Stock Disposition 2020-10-21 3,500 $17.68 70,513 No 4 S Direct
Common Stock Disposition 2020-10-21 2,544 $19.02 67,969 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to$17.92 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of theSecurities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price withinthe range set forth in this footnote.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to$18.08 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of theSecurities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price withinthe range set forth in this footnote.
  4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.21 to $18.01 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.